Brief: Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents
19/02/2026 21:35
Feb 19 (Reuters) - Corcept Therapeutics Inc CORT.O: CORCEPT PROVIDES UPDATE ON PATENT DISPUTE WITH TEVA PHARMACEUTICALS CORCEPT THERAPEUTICS INC - RULING AFFIRMS DECEMBER 2023 VERDICT BY FEDERAL DISTRICT COURT CORCEPT THERAPEUTICS INC - US COURT RULES TEVA'S GENERIC KORLYM DOES NOT INFRINGE CORCEPT PATENTS CORCEPT THERAPEUTICS INC - CONSIDERING JUDICIAL REVIEW OF COURT DECISION Source text: ID:nBwbVM1cFa Further company coverage: CORT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corcept Therapeutics Incorporated
See all newsDrugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
Live Markets: US earnings forecast jumps further after key reports this week
Live Markets: Who's next for the S&P 500? The clock is ticking
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary